Si Ni Tang and Septic Shock
Even though there are continually upgraded recommendations
for managing sepsis, such as "Surviving Sepsis Campaign: international guidelines
for management of severe sepsis and septic shock", mortality is still
high. Si-ni-tang, a remedy documented in Shanghan Lun, a medical collection
from ancient China, is used for treating patients with sepsis and septic shock.
Using a well-designed clinical trial, we are eager to survey the effectiveness
of the concurrent use of this remedy in restoring these patients' hemodynamic
status, or "Yang Qi". Patients admitted to our medical intensive care
units with the diagnosis of septic shock, defined as persistent hypotension
induced by sepsis despite adequate fluid resuscitation, are eligible for
participation. The inclusion criteria include: age from 20 to 85 years,
conditions meeting the definition of septic shock, use of vasopressors within
24 hours of entering the study, and use of a nasogastric tube for feeding. The
enrolled patients are randomly allocated either to the si-ni-tang group or the
placebo group. The prescription of the trial drugs (si-ni-tang/placebo) is 2.25
grams 4 times a day for 7 days or till shock reversal (if shock reversal occurs
in less than 7 days). Data, including duration of vasopressor infusion, gender,
age, co-morbidities, APACHE II score, predicted mortality, ICU mortality, ICU
length of stay, hospital mortality, hospital length of stay, source of sepsis,
and culture results, are collected for the following analysis. Si-ni-tang is
composed of processed Zingiber officinale, Glycyrrhiza uralensis, and Aconitum
carmichaeli. Zingiber officinale and Glycyrrhiza uralensis are found to have
the ability to reduce pro-inflammatory cytokine production, to inhibit
lipopolisaccharide-induced macrophage activation and function, and to lessen
the bacterial load and suppress acute and chronic inflammation. Aconitum
carmichaeli is known to have vasopressor activity, and positive chronotropic
and inotropic effects. As this remedy has a potential benefit in treating
septic shock patients, we designed a double-blind, prospective, randomized
controlled trial and would like to publish the results and conclusions later.
No comments:
Post a Comment